Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Helen Torley
|
| gptkbp:collaboratesWith |
gptkb:Janssen
gptkb:Pfizer gptkb:Takeda gptkb:AbbVie gptkb:Roche gptkb:Bristol_Myers_Squibb gptkb:argenx |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
immunology
oncology |
| gptkbp:founded |
1998
|
| gptkbp:founder |
gptkb:Gregory_Frost
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquarters_location |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Halozyme Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
ENHANZE drug delivery technology
Hylenex |
| gptkbp:numberOfEmployees |
~300
|
| gptkbp:platform |
recombinant human hyaluronidase (rHuPH20)
|
| gptkbp:specializesIn |
drug delivery
enzymatic technology |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:HALO
|
| gptkbp:website |
https://www.halozyme.com/
|
| gptkbp:bfsParent |
gptkb:Randal_J._Kirk
|
| gptkbp:bfsLayer |
7
|